心脏毒性
蒽环类
医学
荟萃分析
化疗
乳腺癌
肿瘤科
内科学
癌症
作者
Cho‐Han Chiang,Yu-Cheng Chang,Yulin Haw,Jia Yi Tan,Cho‐Hsien Chiang,Yuan Ping Hsia,Cho‐Hung Chiang
出处
期刊:Oncology
[S. Karger AG]
日期:2023-12-15
卷期号:102 (6): 510-514
被引量:1
摘要
<b><i>Introduction:</i></b> Breast cancer is the most common cancer in women with a 5-year survival over 90%. However, anthracycline-based chemotherapy causes significant cardiotoxicity often requiring discontinuation of chemotherapeutic regimen among breast cancer survivors. We conducted a systematic review and meta-analysis to evaluate the efficacy of exercise training in mitigating anthracycline-related cardiotoxicity among women with breast cancer. <b><i>Methods:</i></b> We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases. The outcomes of interest were left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), early to atrial filling velocity (E/A) ratio, maximal oxygen consumption (VO<sub>2</sub> max), and cardiac output (CO). We used the Cochrane risk-of-bias tool for randomized trials (RoB 2) to assess the risk of bias in individual studies. <b><i>Results:</i></b> We identified a total of 596 articles with 5 trials included in the final analysis. Exercise training was associated with an increase in VO<sub>2</sub> max compared with no exercise training (mean difference, 3.95 [95% CI, 0.63–7.26]; <i>I</i><sup>2</sup> = 99.68%). Other cardiovascular outcomes such as LVEF (mean difference, 1.76 [95% CI, −1.95 to 5.46]; <i>I</i><sup>2</sup> = 99.44%), GLS (mean difference, 0.30 [95% CI, −0.49 to 1.10]; <i>I</i><sup>2</sup> = 96.63%), E/A ratio (mean difference, 0.05 [95% CI, −0.05 to 0.15]; <i>I</i><sup>2</sup> = 94.16%), and CO (mean difference, 0.38 [95% CI, −0.91 to 1.66]; <i>I</i><sup>2</sup> = 99.73%) are similar between patients who underwent exercise training and those who did not. <b><i>Conclusions:</i></b> Exercise was associated with an improvement in maximal oxygen uptake among women with breast cancer receiving anthracycline-based chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI